Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Purple Biotech ( (PPBT) ) has provided an announcement.
On March 25, 2026, Purple Biotech announced a collaboration with Boston-based Converge Bio to apply generative AI to the design and optimization of its next-generation tri-specific antibody platform for solid tumors. The partnership builds on prior work between the companies and uses Converge Bio’s validated AI technology to accelerate discovery timelines, improve candidate quality and manufacturability, and expand Purple Biotech’s pipeline beyond its CAPTN-3 lead candidates IM1240 and IM1305.
By integrating AI-driven molecule design with its conditional-activation CAPTN-3 technology, Purple Biotech aims to sharpen its positioning at the intersection of immuno-oncology and AI-enabled drug discovery. The move underscores a strategic push to address additional high-value oncology targets and resistance mechanisms, potentially enhancing the company’s competitiveness in multi-specific antibody therapies and supporting future development and partnering prospects for its broader oncology pipeline.
The most recent analyst rating on (PPBT) stock is a Sell with a $4.00 price target. To see the full list of analyst forecasts on Purple Biotech stock, see the PPBT Stock Forecast page.
Spark’s Take on PPBT Stock
According to Spark, TipRanks’ AI Analyst, PPBT is a Neutral.
The score is held down primarily by weak financial performance (minimal revenue, widening losses, and continued cash burn alongside a shrinking equity base). Technicals are also bearish with negative momentum and price below key moving averages, only partially offset by oversold signals. Valuation contributes little support due to unprofitability and no dividend data.
To see Spark’s full report on PPBT stock, click here.
More about Purple Biotech
Purple Biotech Ltd. is a clinical-stage immuno-oncology company headquartered in Rehovot, Israel, and listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker PPBT. It is developing a next-generation immunotherapy platform, led by its CAPTN-3 masked tri-specific antibodies that target tumors while engaging T cells and NK cells, alongside additional clinical-stage assets such as CM24 and NT219 for difficult-to-treat cancers.
Average Trading Volume: 12,954
Technical Sentiment Signal: Strong Sell
Current Market Cap: $5.95M
For a thorough assessment of PPBT stock, go to TipRanks’ Stock Analysis page.